The process typically begins with fragment-based drug discovery, where a library of small, low molecular weight compounds (fragments) is screened against the target protein. The goal is to identify fragments that bind to the target, even if they have low affinity or selectivity. The non-selective hit in this context would be a fragment that binds to FLT3 but lacks specificity.
If you need to purchase chemical raw materials, submit your demand information to get the latest quotations.
1H-Indazole-3-carboxamide, N-(2-methylphenyl)-
